Eli Lilly Cash Flow from Investing Activities 2012-2026 | LLY
Eli Lilly annual/quarterly cash flow from investing activities history and growth rate from 2012 to 2026. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
- Eli Lilly cash flow from investing activities for the quarter ending March 31, 2026 was $-10.972B, a 17.96% increase year-over-year.
- Eli Lilly cash flow from investing activities for the twelve months ending March 31, 2026 was $-27.681B, a 30.35% increase year-over-year.
- Eli Lilly annual cash flow from investing activities for 2025 was $-10.972B, a 17.96% increase from 2024.
- Eli Lilly annual cash flow from investing activities for 2024 was $-9.302B, a 30.04% increase from 2023.
- Eli Lilly annual cash flow from investing activities for 2023 was $-7.153B, a 90.08% increase from 2022.
|
Eli Lilly Annual Cash Flow Investing (Millions of US $) |
|
|---|---|
| 2025 | $-10,972 |
| 2024 | $-9,302 |
| 2023 | $-7,153 |
| 2022 | $-3,763 |
| 2021 | $-2,868 |
| 2020 | $-2,259 |
| 2019 | $-8,083 |
| 2018 | $1,906 |
| 2017 | $-3,784 |
| 2016 | $-3,139 |
| 2015 | $27 |
| 2014 | $-3,909 |
| 2013 | $-2,073 |
| 2012 | $-2,833 |
| 2011 | $-4,824 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $887.629B | $65.179B |
| Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |